PFE
💊 Pfizer has stopped the development of its daily weight-loss pill, Danuglipron, after a patient experienced potential drug-induced liver injury during a trial.
📉 Despite the setback, Pfizer states its commitment to advancing other promising programs in its pipeline.
📊 The stock showed volatility but recovered. Valuation metrics like a low forward P/E (around 7) and a high dividend yield (nearly 8%) are noted amidst the news.
@bernardodegarcia:
“Pfizer crashes but recovers, as we have a slight problem with a small announcement because it will halt the development of its daily pill for weight loss. This occurs after a patient suffered a liver injury, possibly caused by the drug during a trial. ‘While we are disappointed to discontinue the development of Danuglipron,’ I think it was called, ‘we remain committed to evaluating and advancing promising programs to deliver innovative medicines to patients,’ declared Dr. Chris Boshoff, Chief Scientific Officer of Pfizer, in a statement. As you are seeing, we have a lot of volatility, but well, Pfizer shares, I think, more or less the same as we discussed with all those… How much risk do we have buying Pfizer at a forward P/E of 7 when it’s already at $23? Is it particularly undervalued? Well, at $21, where it is right now, right? Well, there we have it. Fair dividend of 7.85%. I don’t know what they will be able to do with this anyway.”
Watch the exact part of the video where @bernardodegarcia talks about Pfizer here:
Watch the video on YouTube
Read more articles analyzing Pfizer (PFE) at the following link. PFE stock.
